Company

Technology

Discover scalable, instrument-free single cell sequencing technology from Parse Bioscience

Technology Overview


Resources

Explore our collection of resources to learn more about technology and its applications from leading researchers

Resources Overview

Company

Providing researchers single cell sequencing with unprecedented scale and ease

About Parse

Technology

Discover scalable, instrument-free single cell sequencing technology from Parse Bioscience

Technology Overview

Transcriptional Analysis of Parkinson’s Disease Using Patient-derived Cells


In this pilot experiment, two sporadic Parkinson’s patient-derived induced pluripotent stem cells (iPSCs) samples and two healthy controls were differentiated into dopaminergic neuronal precursor cells (DA-NPCs).

Each sample was prepared in triplicate, to explore batch effects, robustness, and differential gene expression – for a total of twelve samples. The samples were then fixed with Evercode Cell Fixation v2 and barcoded using the Evercode WT Mini v2 kit.

The results of this work are furthering our efforts to expand the collection and differentiation of additional patient lines. The Early Drug Discovery Unit’s ultimate goal is scaling up this research to identify novel biomarkers and mechanistic targets for new drug development.

Sample Table

Sample Name
(Sample Group + (B) + Sample No.)
Disease Status
x3448B1Healthy Control
x3448B2
x3448B3
TD22B1Healthy Control
TD22B2
TD22B3
x2965B1Sporadic Parkinson’s Disease
x2965B2
x2965B3
TD07B1Sporadic Parkinson’s Disease
TD07B2
TD07B3

 

The Neuro’s Early Drug Discovery Unit operates under the principles of Open Science. To access our protocols and read about our ongoing research, visit https://www.mcgill.ca/neuro/research/eddu.

"We fix samples when they are ready, putting us in charge of our experimental timing."

-Taylor Goldsmith, Early Drug Discovery Unit, Neuro-McGill University

We're your partners in single cell

Reach out for a quote or for help planning your next experiment.